Teva
Highly Engaged Employees
Manufacturing · Israel · 10K+ Employees
View Company Info for Free
Overview
Headquarters
124 Dvora Hanevi'a St, Tel Aviv, Tel Avi...Phone Number
+972 39148213Website
www.tevapharm.comRevenue
$17.3 BillionStock Symbol
TEVAIndustry
About Teva
Teva Org Chart
Is Teva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Teva has new funding data
Website visits: Recent activity has been detected on your website
Teva, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Teva has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Teva launches new products
Click to see if Teva had a recent Job posting/layoffs
Earning: See what the market has to say on Teva recently announced quarterly report
Check out if Teva is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Teva
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Teva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Teva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Teva.
Teva financials insights
Gather financial insights about Teva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Multiple Rounds
$11.3B
Multiple Rounds
$7.6B
Debt
$2.4B
Debt
$33.8B
Multiple Rounds
$28.1B
Corporate Investment
$358M
Debt
$4.5B
Debt
$2.3B
Private Equity
$400M
Teva Tech Stack
A closer look at the technologies used by Teva
Most Recent Scoops
Teva News & Media
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizophrenia remain on treTeva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-'749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-'749 as a once-monthly subcutaneous long-acting injectable (LAI) formulatioTeva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for healthcare providers (HCPs) with information to support informed treatment discussions and decision-making around the role of long-acting injectables (LAIs) in schizophrenia care. This bespoke resource is intended to equip clinicians with key
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Teva
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is... Read More
